Issued: April 19, 2024
Main contents: Where the production of a domestically marketed foreign produced pharmaceutical is to switch to mainland China, the application shall be submitted by
National Medical Products Administration, Announcement on Matters Relating to Optimizing the Application for Registration of the Marketing of a Domestically Marketed Foreign Produced Pharmaceutical the Production of Which is to Switch to Mainland China
国家药监局关于优化已在境内上市的境外生产药品转移至境内生产的药品上市注册申请相关事项的公告
Procedures are facilitated for marketing of domestically produced foreign pharmaceuticals
By
Susan Mok